Pluri (PLUR) Competitors $4.96 -0.10 (-1.98%) (As of 11:15 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PLUR vs. VVOS, CASI, RANI, SCLX, COYA, DERM, VXRT, AVTX, ANRO, and INMBShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Vivos Therapeutics (VVOS), CASI Pharmaceuticals (CASI), Rani Therapeutics (RANI), Scilex (SCLX), Coya Therapeutics (COYA), Journey Medical (DERM), Vaxart (VXRT), Avalo Therapeutics (AVTX), Alto Neuroscience (ANRO), and INmune Bio (INMB). These companies are all part of the "medical" sector. Pluri vs. Vivos Therapeutics CASI Pharmaceuticals Rani Therapeutics Scilex Coya Therapeutics Journey Medical Vaxart Avalo Therapeutics Alto Neuroscience INmune Bio Pluri (NASDAQ:PLUR) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Is PLUR or VVOS more profitable? Vivos Therapeutics has a net margin of -86.19% compared to Pluri's net margin of -4,184.28%. Vivos Therapeutics' return on equity of -335.04% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-4,184.28% -917.18% -82.85% Vivos Therapeutics -86.19%-335.04%-93.58% Do analysts recommend PLUR or VVOS? Vivos Therapeutics has a consensus price target of $6.30, suggesting a potential upside of 117.99%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in PLUR or VVOS? 16.6% of Pluri shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 10.2% of Pluri shares are held by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation & earnings, PLUR or VVOS? Vivos Therapeutics has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$598K47.04-$20.89M-$6.03-0.84Vivos Therapeutics$13.80M1.01-$13.58M-$5.68-0.51 Does the media favor PLUR or VVOS? In the previous week, Vivos Therapeutics had 9 more articles in the media than Pluri. MarketBeat recorded 9 mentions for Vivos Therapeutics and 0 mentions for Pluri. Vivos Therapeutics' average media sentiment score of 0.27 beat Pluri's score of -0.47 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Pluri Neutral Vivos Therapeutics Neutral Does the MarketBeat Community favor PLUR or VVOS? Vivos Therapeutics received 15 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformPluriN/AN/AVivos TherapeuticsOutperform Votes1557.69% Underperform Votes1142.31% Which has more volatility and risk, PLUR or VVOS? Pluri has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.71, suggesting that its stock price is 671% more volatile than the S&P 500. SummaryVivos Therapeutics beats Pluri on 14 of the 17 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.13M$2.93B$5.06B$8.82BDividend YieldN/A1.89%5.18%4.07%P/E Ratio-0.8445.61126.3117.81Price / Sales47.04360.261,178.7474.57Price / CashN/A160.0933.8632.53Price / Book5.063.734.684.68Net Income-$20.89M-$41.63M$119.54M$226.08M7 Day Performance-7.16%-4.73%-1.83%-1.04%1 Month Performance6.53%-6.53%-3.60%1.04%1 Year Performance9.24%25.63%31.91%26.28% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri0.1524 of 5 stars$4.96-2.0%N/A+11.5%$27.58M$330,000.00-0.82150VVOSVivos Therapeutics2.1857 of 5 stars$2.89flat$6.30+118.0%-34.2%$13.99M$13.80M0.00160Analyst ForecastCASICASI Pharmaceuticals3.802 of 5 stars$5.25-0.2%$6.00+14.3%+0.4%$81.17M$33.88M0.00180RANIRani Therapeutics3.1632 of 5 stars$2.02-1.5%$11.71+479.9%+2.5%$107.89M$2.72M0.00110Analyst ForecastSCLXScilex3.4335 of 5 stars$0.56-0.9%$11.33+1,924.5%-48.7%$107.36M$46.74M0.0080Gap UpCOYACoya Therapeutics3.0472 of 5 stars$6.39+6.0%$16.67+160.8%+10.6%$106.78M$6M0.006DERMJourney Medical3.2183 of 5 stars$5.15-1.5%$9.38+82.0%N/A$106.76M$79.18M-5.5690Analyst RevisionNews CoverageVXRTVaxart2.1538 of 5 stars$0.60-1.2%$3.00+399.7%-22.1%$106.53M$7.38M-1.48109Analyst RevisionNews CoverageAVTXAvalo Therapeutics2.3577 of 5 stars$10.20-6.4%N/A-47.4%$105.98M$1.92M0.0040Positive NewsANROAlto Neuroscience3.8056 of 5 stars$3.90-8.7%$20.00+412.8%N/A$105.18M$210,000.000.00N/AAnalyst RevisionINMBINmune Bio2.1308 of 5 stars$4.73+3.7%$20.00+322.8%-39.1%$104.86M$160,000.00-2.0910 Related Companies and Tools Related Companies Vivos Therapeutics Competitors CASI Pharmaceuticals Competitors Rani Therapeutics Competitors Scilex Competitors Coya Therapeutics Competitors Journey Medical Competitors Vaxart Competitors Avalo Therapeutics Competitors Alto Neuroscience Competitors INmune Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PLUR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLUR Stock Alerts